Clinical research progress on RRx−001
10.12206/j.issn.2097-2024.202402028
- VernacularTitle:新药RRx−001的临床研究进展
- Author:
Yangyang GONG
1
;
Chunyang LOU
2
;
Huojun ZHANG
2
;
Zhenyuan MIAO
2
Author Information
1. Class of 2019, Clinical Eight-Year Program, b. The First Affiliated Hospital, c.Class of 2020, Undergraduate Program of Pharmacy, d. School of Pharmacy, Naval Medical University, Shanghai 200433, China;Class of 2019, Clinical Eight-Year Program, b. The First Affiliated Hospital, c.Class of 2020, Undergraduate Program of Pharmacy, d. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
2. Class of 2019, Clinical Eight-Year Program, b. The First Affiliated Hospital, c.Class of 2020, Undergraduate Program of Pharmacy, d. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
- Publication Type:Reviews
- Keywords:
RRx−001;
tumor immunology;
clinical trials
- From:
Journal of Pharmaceutical Practice and Service
2026;44(5):233-238
- CountryChina
- Language:Chinese
-
Abstract:
It is difficult to treat malignant tumors, neurodegenerative diseases, and vascular diseases. For pathogenesis complexity of these diseases, researchers have focused on finding more drugs with high efficacy and low side effects. As a potential first-in-class drug, RRx−001 is expected to be an important first-line drug in tumor immunology, radiosensitizer and radio protecter. Currently, RRx−001 entered phase Ⅲ clinical trials. The data of the phase Ⅱ clinical trials demonstrated its safety and effectivity as a single agent and in combination with first-line clinical drugs. The novel mechanisms of RRx−001 and the result of main clinical trials were summarized, which could be valuable to further optimization and clinical application.
